Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 13/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13117752 | 0.90 | FFAR1 (0.42) | CD274FFAR1PDCD1CYP2D6ALDH1A1 | |
| SCHEMBL12578350 | 0.89 | FFAR1 (0.46) | CD274FFAR1ALDH1A1 | |
| SCHEMBL13092110 | 0.85 | CD274 (0.37) | CD274FFAR1PDCD1ALDH1A1POLB | |
| SCHEMBL13117700 | 0.85 | CD274 (0.41) | CD274FFAR1PDCD1KDM4E | |
| SCHEMBL13117695 | 0.85 | FFAR1 (0.41) | CD274FFAR1PDCD1KDM4E | |
| SCHEMBL13117706 | 0.85 | FFAR1 (0.41) | CD274FFAR1PDCD1KDM4E | |
| SCHEMBL12578280 | 0.84 | CD274 (0.45) | CD274FFAR1PDCD1KDM4E | |
| SCHEMBL2022943 | 0.83 | CD274 (0.38) | CD274FFAR1PDCD1ALDH1A1POLB | |
| SCHEMBL13091947 | 0.82 | CD274 (0.36) | CD274FFAR1PDCD1ALDH1A1POLB | |
| SCHEMBL13091946 | 0.82 | CD274 (0.36) | CD274FFAR1PDCD1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186909-A1 | Oxadiazolidinedione Compound | GPR119, GPR39, GPR65 | CD274 2600/4885FFAR1 64/4885PDCD1 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.